RNAi-based glyconanoparticles trigger apoptotic pathways for in vitro and in vivo enhanced cancer-cell killing by Conde, J. et al.
Nanoscale
PAPER
Cite this: Nanoscale, 2015, 7, 9083
Received 30th September 2014,
Accepted 14th April 2015
DOI: 10.1039/c4nr05742b
www.rsc.org/nanoscale
RNAi-based glyconanoparticles trigger apoptotic
pathways for in vitro and in vivo enhanced
cancer-cell killing†
João Conde,‡a Furong Tian,‡b Yulan Hernandez,c Chenchen Bao,d
Pedro V. Baptista,e Daxiang Cui,d Tobias Stoeger*b and Jesus M. de la Fuente*c,d,f
Gold glyconanoparticles (GlycoNPs) are full of promise in areas like biomedicine, biotechnology and
materials science due to their amazing physical, chemical and biological properties. Here, siRNA
GlycoNPs (AuNP@PEG@Glucose@siRNA) in comparison with PEGylated GlycoNPs (AuNP@PEG@Glucose)
were applied in vitro to a luciferase-CMT/167 adenocarcinoma cancer cell line and in vivo via intratracheal
instillation directly into the lungs of B6 albino mice grafted with luciferase-CMT/167 adenocarcinoma
cells. siRNA GlycoNPs but not PEGylated GlycoNPs induced the expression of pro-apoptotic proteins
such as Fas/CD95 and caspases 3 and 9 in CMT/167 adenocarcinoma cells in a dose dependent manner,
independent of the inflammatory response, evaluated by bronchoalveolar lavage cell counting. Moreover,
in vivo pulmonary delivered siRNA GlycoNPs were capable of targeting c-Myc gene expression (a crucial
regulator of cell proliferation and apoptosis) via in vivo RNAi in tumour tissue, leading to an ∼80%
reduction in tumour size without associated inflammation.
Introduction
Carbohydrates are, together with nucleic acids and proteins,
important molecules for life. Although individual carbohydrate
interactions are relatively weak, nature utilizes multivalent
interactions between these cell surface ligands and their
respective biological receptors to modulate biological events
such as the ones related to cell adhesion, normal tissue growth
and repair, viral/bacterial infection, signal transduction, trap-
ping of leukocytes, and gene transfer. So the decoding of
carbohydrate interactions opens up the possibility to employ
physiologically inert gold nanoclusters in diagnostics and/or
therapy.1 Among them, gold glyconanoparticles (GlycoNPs)
have drawn more attention owing to their well-defined features
as water-soluble carbohydrate-functionalized nanoclusters
with promising potential for chemical glycobiology, biomedi-
cine, diagnostics and clinical applications. In the last 10 years,
de la Fuente and co-workers have extensively reported a pioneer-
ing integrated glyconanotechnology strategy. Based on the use
of these nanoparticles they studied and evaluated carbohydrate–
carbohydrate, and carbohydrate–protein interactions,2–6 and
further used these nanoparticles as potential tools in anti-
adhesive therapy,7 for cell–cell adhesion studies8 and for the
prevention of pathogen invasion.9
Small carbohydrates such as glucose can be attached to
gold nanoparticles (AuNPs) and thereby used for sensitive
colorimetric assays.10 However, to the best of our knowledge
the use of siRNA GlycoNPs in the regulation of important
genes of the apoptotic pathways has never been described.
Herein, a novel structure of multifunctional RNAi-based
GlycoNPs functionalized with glucose, poly(ethylene glycol)
(PEG), a biotin linked fluorophore and cMyc targeting siRNA
was designed to trigger apoptosis and gene silencing pathways
(see Fig. 1). Through a chemical approach, the functional pro-
perties and moieties of this kind of multifunctional nano-
structure can be easily tuned and quantified as recently
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reported by our group.11,12 In fact, we have provided evidence
of in vitro and in vivo efficient RNAi via the synthesis of a
library of novel multifunctional AuNPs, tested in three biologi-
cal systems of increasing complexity: in vitro cultured human
cells (HeLa cells), in vivo freshwater polyp (Hydra vulgaris), and
in vivo mice models (B6 albino mice).11,13
In view of the great number of studies concerning glucotoxi-
city attributed to the inability of cells to reduce glucose uptake
when exposed to chronic hyperglycemia, we designed novel
siRNA GlycoNPs that predispose gene expression to apoptosis
via enhancement of cell death receptors. In fact, it is known
that high levels of glucose induce apoptosis via upregulation
of cell death receptors – Fas – providing a link between type 1
and type 2 diabetes.14,15 Hyperglycemia is the central initiating
factor for all types of diabetic microvascular disease. Studies
on endothelial cell cultures clearly show glucose toxicity by
delaying replication, disturbing the cell cycle, increasing DNA
damage and accelerating cell death.16,17
Maedler et al. also reported that increased glucose concen-
tration by itself induces apoptosis in human pancreatic β-cells
via the upregulation of Fas receptors, which can interact with
the constitutively expressed FasL (Fas ligand) on neighbouring
β-cells. Fas–FasL interaction leads to cleavage of procaspase-8
to caspase-8, which promotes caspase-3 activation.14 The
stimulation of death receptors such as Fas (APO-1/CD95) and
creation of DISC (death-inducing signalling complex) are com-
monly considered as the starting point in the extrinsic apopto-
sis execution phase, whereas caspase-9 activation is a
downstream marker for mitochondrial membrane permeabili-
sation in the intrinsic apoptotic pathway.18 Both pathways con-
verge on the same terminal outcome, which is initiated by the
cleavage of caspase-3 and results in DNA fragmentation, degra-
dation of cytoskeletal and nuclear proteins, formation of apop-
totic bodies, expression of ligands for phagocytic cell receptors
and finally clearance by phagocytic cells.
Herein, the in vitro and in vivo activation of apoptotic and
gene silencing pathways via RNAi GlycoNPs will be investigated
and the clinical outcome in terms of lung cancer progression
will be evaluated.
Results and discussion
Glyconanoparticle synthesis and characterization
Multifunctional gold glyconanoparticles were prepared by
reduction of sodium tetrachloroaurate(III) hydrate with sodium
citrate as described by Turkevich and Frens,19,20 and stabilized
with poly(ethylene glycol) (PEG) and subsequent conjugation
Fig. 1 (A) Multifunctional siRNA glyconanoparticles (siRNA GlycoNPs) trigger apoptotic pathways (B) with the expression of cell death receptors
(Fas) and caspases. The death domain-containing receptor Fas can sense an external signal and activate the apoptosis pathway through the Fas-
related death domain. This pathway is mediated by the activation of caspase-8, followed by direct cleavage of downstream effector caspases. The
apoptosis pathway can also be initiated in the cytoplasm through activation of intracellular changes resulting in the release of proapoptotic factors
from the mitochondria. The release of these factors leads to the activation of caspase-9, and ultimately results in the activation of effector caspases
(e.g. caspase 3) and consequently to cell death by apoptosis. (C) The siRNA glycoNPs also have the capacity to trigger gene silencing via activation
of the RNA interference pathway, by small interfering RNA (siRNA), promoting nucleolytic degradation of the target mRNA and/or translational
suppression.
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with glucose, biotin and siRNA. Briefly, the obtained AuNPs,
with an average diameter of 14 nm, were subsequently functio-
nalized with two types of thiolated PEG – a commercial car-
boxylated PEG (HS–EG(8)–(CH2)2–COOH) and another one
synthesized in our lab with an azide group at the end
(HS–(CH2)3–CONH–EG(6)–(CH2)2–N3) – by exchange of the
citrate groups. For the subsequent attachment of thiolated
siRNA using the covalent approach previously described,11 the
AuNPs were functionalized with a 40% degree of coverage of
the surface using 50% of each PEG chain.
Once stable and biocompatible PEGylated AuNPs were
obtained we functionalized them with amine-modified biotin
and glucose through an EDC coupling reaction forming amide
bonds with the carboxylic groups exposed on the surface. The
covalent conjugation of the biotin was evaluated by the cross-
linking induced by the effective attachment of streptavidin to
up to four biotin molecules and also determined by indirect
quantification by the Bradford assay. Concerning the attach-
ment of glucose, the change of the net charge and the aggrega-
tion of the AuNPs effectively functionalized in the presence of
the lectin Concanavalin A (Con A)21 were used to confirm the
conjugation, again via the occurrence of crosslinking induced
due to the multi-interaction between glucose and Con A. Lastly,
GlycoNPs were functionalized with thiolated anti-cMyc siRNA
through direct attachment of the thiol group to the gold core of
the AuNP by establishing strong pseudo-covalent bonds Au–S
(for further details on synthesis, functionalization and quantifi-
cation methods for siRNA gold glycoNPs see the ESI†).
Triggering apoptotic pathways via glyconanoparticles
The functionalized nanoparticles were administered in vitro to
a luciferase-CMT/167 adenocarcinoma cancer cell line and
in vivo via instillation directly into the lungs of cancer mice (B6
albino mice induced with luciferase-CMT/167 adenocarcinoma
cells). Upon 48 hours of treatment with increasing concentrations
(10, 100 and 200 µg mL−1) of PEGylated GlycoNPs (AuNP@
PEG@Glucose) and siRNA GlycoNPs (AuNP@PEG@Glucose@
siRNA) cells were assessed for the expression of proapoptotic
proteins such as Fas/CD95 and caspases-3 and -9, as well as
the siRNA target c-Myc gene that also triggers apoptosis in
association with tumour suppressors such as ARF and p53.22
Representative confocal images of luciferase-CMT/167 adeno-
carcinoma-loaded cells show that siRNA GlycoNPs accomplish
high cellular uptake (3-fold) and trigger apoptosis by enhancing
the expression of the Fas death receptor, as detected by a signifi-
cant increase (2-fold) of Fas/CD95 fluorescence (Fig. 2A).
Glucose-surface functionalization has also been developed
for siRNA GlycoNPs as a metabolic transporter to enhance the
uptake of the therapeutic nanoparticles by cancer cells. In fact,
tumour cells display a high rate of glucose uptake and glycoly-
sis, since cell proliferation requires increased uptake of nutri-
ents (e.g. glucose and glutamine). Cancer cells exhibit a high
rate of glycolysis even in the presence of oxygen (aerobic
glycolysis).23 The major function of aerobic glycolysis is to
maintain high levels of glycolytic intermediates to support ana-
bolic reactions in cells. This explains increased glucose metab-
olism in proliferating cells.18 In addition to cell proliferation,
increased glucose uptake may also be associated with mitochon-
dria damage in cancer cells, or an adaptation to hypoxia environ-
ments within tumours or to mitochondria shutdown by cancer
genes (e.g. c-Myc) involved in the cell’s apoptosis program.23,24 In
fact, high glucose levels proved to be pro-apoptotic, increasing
the sensitivity to apoptosis via Fas activation.14
Our results suggest that siRNA GlycoNPs activate apoptotic
pathways by regulating cell death receptors and effective cas-
pases, and the effect is dose dependent. Increasing concen-
trations (10, 100 and 200 µg mL−1) of siRNA GlycoNPs show
enhancement in Fas expression in a dose dependent manner,
as it can be seen by an increase of Fas/CD95 fluorescence (see
Fig. 2B) 1.5-fold from 10 to 100 µg mL−1 and 3-fold from
100 to 200 µg mL−1 of NPs.
In order to corroborate these data and evaluate siRNA Gly-
coNPs’ involvement in the activation of crucial proapoptotic
proteins, expression of Fas, caspase-3 and caspase-9 was
assessed by western blotting in the luciferase-CMT/167 adeno-
carcinoma cancer cell line. The expression of Fas, activated/
cleaved caspase-3 and caspase-9 proteins was significantly
higher (5 fold) for siRNA GlycoNPs at 10, 100 and 200 µg mL−1
compared to PEGylated GlycoNPs (Fig. 3A).
Fig. 2 Gold siRNA glyconanoparticles trigger apoptotic pathways via
expression of the Fas cell death receptor. (A) Immunostaining of Fas/
CD95 in luciferase-CMT/167 adenocarcinoma cells treated with 200 µg
mL−1 of PEGylated glycoNPs and siRNA GlycoNPs for 48 hours. Cells
stained for DAPI (nuclei) in blue, actin (phalloidin) in green, Fas/CD95
stained in red and NPs (conjugated streptavidin with Cy7-Allophycocya-
nin bound with biotin) in white (scale bars, 20 μm). (B) Immunostaining
of Fas/CD95 in luciferase-CMT/167 adenocarcinoma cells treated with
10, 100 and 200 µg mL−1 of siRNA GlycoNPs. Cells stained for Fas/CD95
in red and NPs (conjugated streptavidin with Cy7-Allophycocyanin
bound with biotin) in green (scale bars, 20 μm). The results shown are
representative for at least three independent experiments.
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The expression of Fas and caspase-3 and -9 from cells
treated with 10 µg mL−1 of siRNA GlycoNPs indicates the
strong activation of both intrinsic and extrinsic apoptotic path-
ways. Enhanced activation of caspase-9 by siRNA GlycoNPs can
especially be observed at 200 µg mL−1 (see Fig. 2), which in
turn may induce the activation of procaspase-3, which leads to
the apoptosome formation.24 Once formed, the apoptosome
can then recruit and activate the inactive pro-caspase-9, which
can activate effector caspases and trigger a cascade of events
leading to apoptosis. Finally, after the activation of caspase-9,
the effector caspase-3 is activated and marks the endpoint of
apoptosis.24
This finding further supports the notion that siRNA Gly-
coNPs promote apoptosis within the luciferase-CMT/167
adenocarcinoma cancer cell line when exposed for 48 hours at
a concentration of 100 and 200 µg ml−1 (Fig. 3A and C). PEGy-
lated GlycoNPs showed no changes in expression of the
assessed cell death receptor or caspases (Fig. 3A and C).
Several studies were published in the last years reporting that
some engineered AuNPs induce apoptosis in cells via caspase
pathways.25–30 Our platform comprises a new and smart siRNA
gold glycoNP system capable of inducing apoptosis via hyper-
activation of cell death receptors and caspases pathways.
RNAi-based GlycoNPs were also functionalized with a
siRNA to mediate silencing of c-Myc gene expression. c-Myc is
widely known as a crucial regulator of cell proliferation in
normal and neoplastic cells, and recent reports strongly
support a dual function model for c-Myc as a co-ordinate acti-
vator of cell proliferation and apoptosis.28 Several studies
provide evidence that c-Myc function is closely related to apop-
tosis and that the induction or inhibition of apoptosis by this
protein may depend on the level of expression or cell lineages
used.31 To assess whether anti-cMyc siRNA GlycoNPs attenuate
MYC protein synthesis, its expression was also evaluated by
western blotting in the luciferase-CMT/167 adenocarcinoma
cancer cell line (Fig. 3B and C) after exposure to PEGylated
GlycoNPs and siRNA GlycoNPs. Western blotting results clearly
show that c-Myc downregulation (14-fold) is attained with only 10
µg mL−1 of siRNA GlycoNPs (Fig. 3B and C). PEGylated GlycoNPs
show no silencing effect for all NP concentrations (Fig. 3B and C).
In vivo RNAi triggering via siRNA glyconanoparticles
For in vivo evaluation of the effect of GlycoNP treatment on
c-Myc expression in a mouse lung tumour model, 200 µg mL−1
of PEGylated GlycoNPs and siRNA GlycoNPs were administered
to mice previously inoculated with luciferase-CMT/167 adeno-
carcinoma cells. Four weeks after orthotropic lung cancer
induction mice were treated by instillation of 0.3 pmol AuNPs
(at weeks 12, 13, 14 and 15), respectively, in 50 μl pyrogen-free
distilled water, followed by 100 μl of air. Fig. 4A shows Hema-
toxylin and Eosin staining (H&E) and immunolocalisation of
c-Myc expression in mice lung tissues for sham, PEGylated Gly-
coNPs and siRNA GlycoNPs groups. The PEGylated GlycoNP
treated group demonstrates a cancer lung tissue characterized
by hypercellularity and thickened alveolar septa. Cancer cells
have spread throughout the lung tissue, and large areas of
deformed lung structures can be observed (Fig. 4A). Severe
interstitial inflammatory cell infiltration is noted in the
PEGylated GlycoNP treated group, with the predominance of
perivascular and peribronchiolar edemas (Fig. 4A arrows). In
the siRNA GlycoNP-treated group in contrast a significant
decrease in the incidence and severity of tumour foci in the
lungs can be observed, revealing the potency of siRNA Gly-
coNPs in reducing the tumour mass in the lung cancer mouse
model. Only a few scattered cancer cells can get localized with
recovered alveolar lung tissue. Concerning confocal images of
lung tissue, Fig. 4B shows high expression of the MYC protein
in the cytoplasm of tumour cells after exposure to PEGylated
GlycoNPs whereas Fig. 4C illustrates tumour cells treated with
siRNA GlycoNPs and shows downregulation of local MYC
expression (6-fold), probably leading tumour cells to apoptosis,
and consequently inhibiting cell proliferation. Moreover,
cancer cells in lung tissue accumulate more siRNA GlycoNPs
(2-fold) (Fig. 4C) than PEGylated GlycoNPs (Fig. 4B). Xing and
co-workers also reported that glucose and antisense
oligodeoxynucleotide-capped AuNPs showed significantly
increased cellular uptake compared to neutral nanoparticles in
breast cancer32 and prostate cancer cells.33
Fig. 3 Activation of the apoptotic pathway via siRNA GlycoNPs. Fas,
Caspase 3, Caspase 9 (A) and c-Myc expression (B) in western blot after
luciferase-CMT/167 adenocarcinoma cancer cells treated with increasing
concentrations (0.1, 1, 10, 100 and 200 µg mL−1) of PEGylated GlycoNPs
and siRNA GlycoNPs. (C) Comparative graph with the expression of Fas,
and activated Caspases 3 and 9 and c-Myc after luciferase-CMT/167
adenocarcinoma cancer cells treated with PEGylated GlycoNPs and siRNA
GlycoNPs. The results shown are representative for at least three indepen-
dent experiments.
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Inflammatory response and in vivo glyconanoparticle
biodistribution in mice
The inflammatory response of the assembled glyco-nanoconju-
gates was evaluated by bronchoalveolar lavage (BAL) cell analy-
sis. Under steady state conditions, the most abundant cells
retrieved in the BAL fluid are the resident alveolar macro-
phages that line the alveolar space (about 98% of BAL cells),
and under inflammatory conditions infiltrating leukocytes
such as lymphocytes and neutrophils. Consequently, evalu-
ation of the number of BAL macrophages, lymphocytes and
neutrophils was used to characterize the inflammatory
response (Fig. 5) upon treatment with PEGylated GlycoNPs and
siRNA GlycoNPs in cancer mice for 1, 3 and 14 days. Fig. 5A
shows representative microscopy images of BAL cells at days
1 and 14 for 200 µg mL−1 of PEGylated GlycoNPs and siRNA
GlycoNPs. Fig. 5B shows evaluation of the number of macro-
phages, lymphocytes and neutrophils in cancer mice for 1, 3
and 14 days after PEGylated GlycoNP and siRNA GlycoNP
instillation. No multinucleated macrophages, indicators of a
foreign body response, are found under any conditions. As
expected,13 the sham treated group (healthy mice without lung
cancer induction of luciferase-CMT/167 adenocarcinoma cells)
reveals intact and normal alveolar macrophages (Fig. 5A).
Inflammatory cells infiltration is noted by increasing numbers
of neutrophils in the siRNA GlycoNP (200 µg mL−1) treated
groups on days 1 and 14 (Fig. 5A). PEGylated and siRNA
GlycoNPs show the same pattern and number of macrophages
as well as neutrophils and lymphocytes (Fig. 5B). The
increased number of neutrophils with 200 µg mL−1 of
PEGylated and siRNA GlycoNPs on day 1 indicates a moder-
ate, acute and over time rapidly declining inflammatory
response, resulting in baseline levels (sham) and thus negli-
gible neutrophil numbers at days 3 and 14 after treatment
(Fig. 5B). No significant changes have been observed for BAL
lymphocyte numbers over the period of investigation, point-
ing to the generally described innate, acute inflammatory
response to pulmonary deposited materials.34,35 No signifi-
cant changes in the number of macrophages and neutrophils
between PEGylated GlycoNPs and siRNA GlycoNPs are
observed (Fig. 5B).
In order to analyse the tumour size, nanoparticle uptake
and biodistribution in the whole body of mice but predomi-
nantly in lung tumour tissue, tomography bioluminescence
Fig. 4 RNAi triggering in mice. (A) Hematoxylin and eosin (H&E) stains of sham (healthy mice without lung cancer induction of luciferase-CMT/167
adenocarcinoma cells), PEGylated GlycoNP and siRNA GlycoNP treated groups in lung tumor tissue. Severe interstitial inflammatory cell infiltration is
noted, with the predominance of perivascular and peribronchiolar edemas (arrows) in PEGylated GlycoNPs only. Immunohistochemical images of
lung tissue of PEGylated GlycoNP (B) and siRNA GlycoNP (C) treated groups. Cells in lung tissue stained for actin in green and MYC stained in red
(scale bars, 100 μm).
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imaging was carried out in the mouse cancer model (B6 albino
female mice injected with luciferase-CMT/167 adenocarcinoma
cells) treated with 200 µg mL−1 of PEGylated GlycoNPs and
siRNA GlycoNPs (Fig. 6). Representative whole body images of
the individual mice from each treated group (n = 8 animals)
shown at a fixed photon flux scale illustrate the luciferase
activity (Fig. 6A). Detection of epi-fluorescence (Fig. 6B)
further allowed localization of nanoparticles conjugated to
streptavidin with Cy7-Allophycocyanin (Cy7APC, BD Pharmin-
gen™) with an excitation wavelength of 642 nm. Fig. 6C and D
show excised organs to evaluate the lung tumour size via the
luminescence of luciferase and Fig. 6E and F show nano-
particle distribution in mice organs via the measurement of
epi-fluorescence of nanoparticles conjugated to streptavidin
with Cy7-Allophycocyanin (Exc = 642 nm).
The tomography images clearly depict that siRNA GlycoNPs
achieved an increased targeting toward lung cancer cells when
compared to PEGylated GlycoNP treatment, which shows no
signal-accumulation in the respective lung tissue, for the
same scale of epi-fluorescence. Once the lung is characterized
by high expression of c-Myc, siRNA anti-cMyc targeting GlycoNPs
seem to accumulate in the tissue more effectively and for a
longer period of time than observed for PEGylated GlycoNPs
only. Moreover, treatment of the murine lung cancer model
with GlycoNPs leads to successful tumour size reduction
(∼80%) as depicted by the decrease in the reporter lumines-
cence signal (Fig. 6A and C), when compared to the PEGylated
GlycoNPs.
Experimental
Synthesis of PEGylated and siRNA GlycoNPs
A full description of synthesis and characterization methods
of PEGylated GlycoNPs and siRNA GlycoNPs can be found in
the ESI.†
Immunostaining of luciferase-CMT/167 adenocarcinoma cells
Cells were fixed with −20 °C methanol for 10 min and with
−20 °C acetone for 1 min on cover slips. The cover slips were
washed twice in PBS, and then blocked with PBS containing
0.1% BSA for 10 min at room temperature followed by drain-
ing. The cell-side-up of the glass slide was incubated with anti-
rabbit Fas (Santa Cruz Biotechnology) in PBS containing 1%
BSA for 60 min, and was washed three times in PBS. The
samples were incubated with Alexa 546 anti-rabbit or FITC 488
anti-rabbit as the secondary antibody and phalloidin (Invitro-
gen), at the recommended dilution, in PBS containing 1%
BSA, for 30 min, and then were washed three times in PBS.
After DAPI staining, one drop of aqueous mounting medium
was added on the cover slip and inverted carefully on the glass
slide. The images were acquired on a Zeiss confocal micro-
Fig. 5 Inflammatory response in bronchoalveolar lavage (BAL) cells in mice during 1, 3 and 14 days of exposure to gold GlycoNPs. (A) Representative
microscopy images of BAL cells (scale bars, 20 μm) at days 1 and 14 for 200 µg mL−1 of PEGylated GlycoNPs and siRNA GlycoNPs. Black arrows indi-
cate neutrophils. (B) Evaluation of the number of macrophages, lymphocytes and neutrophils was used to detect the inflammatory response in the
lungs during 1, 3 and 14 days after PEGylated GlycoNP and siRNA GlycoNP instillation. Sham groups correspond to healthy mice without lung cancer
induction and any nanoparticle treatment. Error bars indicate ±s.d. of n = 6 mice.
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scope and the fluorescence density per cell was analysed by
using ImageJ.
Western blot of Fas/CD95, caspases 3 and 9 expression
Protein extract was boiled in sample buffer for 3 min and
loaded onto 12% SDS-polyacrylamide gel. Details of the
western immunoblotting procedure have been described else-
where.36 The antibodies used in this experiment were as
follows: anti-rabbit Fas (Santa Cruz Biotechnology, 1 : 500
dilution), anti-rabbit caspase3 (cleaved) (Invitrogen, 1 : 500
dilution), anti-rabbit polyclonal caspase9 (cleaved) (Abcam,
1 : 1000 dilution), and anti-rabbit IgG horseradish peroxidase
(Amersham-Pharmacia Biotech, 50 000 : 1 dilution). The blot
was visualized with an ECL kit (Amersham-Pharmacia
Biotech).
In vivo targeting of PEGylated glycoNPs and siRNA GlycoNPs
Prior to glycoNP instillation, B6 albino mice (B6N-Tyrc/
BrdCrCrl, Charles River, France, induced with luciferase-CMT/
167 adenocarcinoma cells) were anesthetized by intraperito-
neal injection of a mixture of medetomidine (0.5 mg per kg
body mass), midazolam (5.0 mg per kg body mass) and fenta-
nyl (0.05 mg per kg body mass). The animals were then intu-
bated using a nonsurgical technique. Using a cannula inserted
10 mm into the trachea, a suspension containing 1 × 105
cancer cells or 200 µg mL−1 of PEGylated GlycoNPs and siRNA
GlycoNPs in 50 μl pyrogen-free distilled water was instilled,
followed by 100 μl air. After instillation the animals were
anaesthesised by subcutaneous injection of a mixture of atipa-
mezole (2.5 mg per kg body mass), flumazenil (0.5 mg per kg
body mass) and naloxone (1.2 mg per kg body mass) and to
control awakening of the mice. Animal experiments were
carried out according to the German law of protection of
animal life and were approved by an external review committee
for laboratory animal care (animal approval number: 55.2-1-54-
2532-20-11). After 72 hours mice lungs were dissected and pre-
pared for Hematoxylin and Eosin staining (H&E) and for
immunolocalisation by a standard immunohistochemical pro-
cedure to verify c-Myc expression and the distribution of NPs
by tissue sections.
Molecular analyses of MYC expression in mice
The lung cancer tissues (from B6 albino mice induced with
luciferase-CMT/167 adenocarcinoma cells) were embedded
and sliced into 3 μm sections. Standard Hematoxylin and
Eosin (H&E) staining was employed for cancer cell morphology
observation. For immunolocalisation, standard immunohisto-
chemical staining methods were employed: the tissue slide
was incubated with anti-mouse c-Myc and anti-rabbit caspase-3
(1 : 1000) in PBS containing 1% BSA for 60 min, and was
washed three times in Tris-buffered saline (TBS). The slide was
incubated with 560 nm anti-mouse and FITC anti-rabbit as the
secondary antibody, at the recommended dilution, in TBS con-
taining 1% BSA, for 30 min, and then was washed three times
in PBS. The slides were mounted with 50 µl of mounting
medium. The images were acquired by Zeiss confocal
microscopy and the fluorescence density per cell was analysed
by using ImageJ.
Preparation of BAL cells/fluid for evaluation of the
inflammatory response
BAL (bronchoalveolar lavage cell) fluid was obtained by inject-
ing 4 times and recovering two 0.5 mL aliquots of PBS via a tra-
cheal cannula. Cells recovered with the lavage fluid
(lymphocytes and neutrophils accompanying the predominant
population of alveolar macrophages) were determined utilizing
light microscopic cell differentiation, counting 200 cells per
cytospin preparation. Details of the bronchoalveolar lavage
procedure were described elsewhere.37 Mice were exposed to
200 µg mL−1 of PEGylated GlycoNPs or siRNA GlycoNPs.
Fig. 6 GlycoNP uptake, whole body biodistribution and tumour size
assessment in mice. Tomography imaging of B6 albino female mice
injected with luciferase-CMT/167 adenocarcinoma cells (n = 8 animals
per treated group) treated with 200 µg mL−1 of PEGylated GlycoNPs and
siRNA GlycoNPs. Representative imaging of individual mice from each
treatment group (n = 8 animals) is shown, with the same scale of
photon flux indicating luciferase activity (A) and epi-fluorescence (B)
indicating nanoparticles conjugated to streptavidin with Cy7-Allophyco-
cyanin (Cy7APC, BD Pharmingen™) with an excitation wavelength of
642 nm. (A, B) Luminescence and epi-fluorescence images of lung
cancer mice treated with 200 µg mL−1 of PEGylated GlycoNPs and
siRNA GlycoNPs. Excised organs to evaluate the lung tumour size via the
luminescence of luciferase in mice treated with PEGylated AuNPs (C)
and gold GlycoNPs (D). Nanoparticle distribution in different organs
treated with PEGylated GlycoNPs (E) and siRNA GlycoNPs (F) via the
measurement of epi-fluorescence of nanoparticles conjugated to strep-
tavidin with Cy7-Allophycocyanin.
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In vivo bioluminescence imaging
Stable clones of CMT64/61 cells, originally derived from spon-
taneous lung adenocarcinoma of a C57Bl/ICRF mouse,32 were
generated by transfection with pGL3-Control vector (Promega
GmbH), and co-transfection for selection with a linear Hygro-
mycin resistance marker (Clontech). A stable clone (CMT/167-
luc) expressing high levels of firefly luciferase, constitutively
driven by the SV40 promoter and enhancer, was instilled into
female C57BL/6 albino mice. Prior to instillation, the mice
were anesthetized by intraperitoneal injection of a mixture of
medetomidine (0.5 mg per kg body mass), midazolam (5.0 mg
per kg body mass) and fentanyl (0.05 mg per kg body mass).
The animals were then intubated using a nonsurgical tech-
nique. Using a cannula inserted 10 mm into the trachea, a sus-
pension containing 1 × 105 CMT/167-luc cells in 50 μl pyrogen-
free distilled water was instilled, followed by 100 μl of air, at
week 8. Four weeks after orthotropic lung cancer induction the
mice were treated by instillation of 0.3 pmol AuNP (at weeks 12,
13, 14 and 15), respectively, in 50 μl pyrogen-free distilled water,
followed by 100 μl of air. After instillation animals were antago-
nized by subcutaneous injection of a mixture of atipamezole
(2.5 mg per kg body mass), flumazenil (0.5 mg per kg body
mass) and naloxone (1.2 mg per kg body mass). Luciferase
expression was monitored applying the IVIS® imaging system
(Lumina, PerkinElmer) frommice bearing tumours from lucifer-
ase-CMT/167 cells (n = 8 animals per treated group).
Conclusions
Several studies have been published in the last few years report-
ing that some engineered gold nanoparticles induce apoptosis in
cells via caspase pathways. Herein, we present for the first time
a new and smart RNAi-based gold glyconanoparticle system
capable of inducing apoptosis via hyperactivation of cell death
receptors and caspase pathways. In summary, we demonstrate
that siRNA GlycoNPs have remarkable potential to trigger
apoptosis via the enhancement of cell death receptors and
activation of caspases. Moreover, our results confirm that
sham, PEGylated GlycoNP and siRNA GlycoNP treated groups
cause the same inflammatory response, proving that siRNA
GlycoNPs trigger apoptotic pathways via expression of cell
death receptors and effective caspases in a specific way, inde-
pendent of the inflammatory response. Consequently, the
switching on of the apoptotic pathways is not caused by any
toxic and/or adverse side effects of the exposure to the NPs in
mice. Most importantly, pulmonary delivery of siRNA Gly-
coNPs leads to a ∼80% reduction in the tumour size via in vivo
RNAi in tumour tissue by targeting c-Myc gene expression.
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